Clinical trial · Interventional
Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy
Concurrent Goserelin During Chemotherapy for Ovarian Function Preservation in Premenopausal Breast Cancer: An Open-Label Randomized Trial
NCT07127315CI-TRIAL-00121544completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and estradiol (E2) levels.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy | — | UNRESOLVED | — |
| Gonadotropin Releasing Hormone Agonists | — | UNRESOLVED | — |
| Ovarian Function | — | UNRESOLVED | — |
| Premenopausal | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Gonadotropin-releasing hormone agonist | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention group
- description
- Patients received chemotherapy with concurrent Goserelin 3.6 mg subcutaneously every 28 days
- interventionNames
- Drug: Gonadotropin-releasing hormone agonist
- type
- ACTIVE_COMPARATOR
- label
- Control group
- description
- Patients received chemotherapy alone.
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Anti-mullerian hormone level
- timeFrame
- Immediately post-procedure (Up to 1 hour)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Premenopausal female patients 18-45 years. * Female patients with pathologically confirmed breast cancer and receiving a chemotherapy regimen, either adjuvant or neoadjuvant, containing a gonadotoxic agent. * Female patients with performance status (PS) ≤ 2. Exclusion Criteria: * All female Patients with metastatic cancer. * Patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy, or patients received radiotherapy on the pelvis. * Patient with end-organ failure. * Patients with performance status \>2. * Male with breast cancer. * Post-menopausal females.
References
Publications (0)
Data not yet available
No reference posted for this study.